Carcinoid Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against carcinoid and guarantee the finest results for our customers all over the world.

Carcinoid

Carcinoid tumor is a slowly growing neuroendocrine tumor that originates from the cells of neuroendocrine system. In some cases, metastasis may occur. They are usually found in the GI tract and arise from enterochromaffin-like cells. However, carcinoids can occur in other anatomical locations. Carcinoid tumors of the midgut (ileum, jejunum, cecum, and appendix) are associated with carcinoid syndrome. Carcinoid is the most common cancer of the appendix, but it is most commonly associated with the small intestine and is also seen in the stomach and rectum. Compared to most malignancies, they grow very slowly, but all carcinoids are considered to have malignant potential.

Therapeutic Vaccines for Carcinoid

A patient with bronchial carcinoid tumor received compassionate treatment with NGcGM3/VSSP Montanide ISA. This is a vaccine containing the glycosphingolypid known as NGcGM3 conjugated with the outer membrane of Neisseria meningitides forming proteoliposomes of very small size (VSSP) and adjuvated with Montanide ISA. NeuGcGM3 is an antigen that is expressed by carcinoids. The vaccine was given in combination with recombinant human IFN-α. With the disease having progressed after treatment with recombinant human IFN-α alone, the patient was immunized five times by the intramuscular route at 2-week intervals and then monthly for more than 1 year. A total of 56 months later, the patient had stable disease.^[1]

Gastric type I carcinoid is a rare neoplasm, deriving from enterochromaffin-like cells (ECL), mainly affecting women with autoimmune gastritis. Three patients with type I gastric carcinoid in autoimmune gastritis were administered with a vaccine against gastrin 17 (G17), a synthetic peptide that stimulates specific and high-affinity anti-G17 antibodies and followed up endoscopically and clinically for a mean of 36 months. Following vaccination, carcinoid regression was observed in 2/3 patients and, in one of the patients, even the disappearance of ECL hyperplasia, with a reduced ECL cells stimulation, confirmed by a significant reduction in chromogranin A levels. Regression was observed in the two patients that showed a clearer local response to the vaccine. Increased autoantibody titre was observed, but no appearance of new autoimmune diseases.^[2]

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the carcinoid vaccines. If you are interested in our services, please contact us for more details.

References

1. Alvarez, MC. (2007). “Bronchial carcinoid tumor treated with interferon and a new vaccine against NeuGcGM3 antigen expressed in malignant carcinoid cells.” Cancer Biol Ther 6(6), 853-855.
2. Tieppo, C. (2011). “Gastric type I carcinoid: a pilot study with human G17DT immunogen vaccination.” Cancer Immunol Immunother 60(7), 1057-1060.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.